Abstract
All human hemoglobins have a tetrameric structure, consisting of two identical α-like (α or ζ) and two β-like (ε, γ, δ, or β) globin chains, each linked to a heme group.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Selected References
Beutler E. Hemoglobinopathies associated with unstable hemoglobin. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw-Hill, 1995.
Bianco I, Cappabianca MP, Foglietta E, et al. Silent thalassemias: genotypes and phenotypes. Haematologica 1997; 82: 269–280.
Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic and Clinical Aspects. Philadelphia: WB Saunders, 1986.
Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317–1322.
Craig JE, Rochette J, Fisher CA, et al. Dissecting the loci controlling fetal haemoglobin production on chromosomes l 1p and 6q by the regressive approach. Nat Genet 1996; 12: 58–64.
Crossley M, Orkin SH. Regulation of the f 3-globin locus. Curr Opin Genet Dev 1993; 3: 232–237.
Dover GJ, Smith KD, Chang YC, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992; 80: 816–824.
Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven, 1994.
Gibbons RJ, Picketts DJ, Villard L, Higgs DR. X-linked mental retardation associated with a thalassaemia (ATR-X syndrome) results from mutations in a putative global transcriptional regulator. Cell 1995; 80: 837–845.
Grosveld F, van Assendelft GB, Breaves DR, Kollias G. Position-independent, high-level expression of the human y-globin gene in trans-genic mice. Cell 1987; 51: 975–985.
Higgs DR, Weatherall DJ. Bailliére’s Clinical Haematology. International Practice and Research: The Haemoglobinopathies. London: Bailliére Tindall, 1993.
Ho PJ, Hall GW, Luo LY, Weatherall DJ, Thein SL. Beta thalassemia intermedia: is it possible to consistently predict phenotype from genotype? Br J Haemat 1998; 100: 70–78.
Lau YL, Chan LC, Chan YY, et al. Prevalence and genotypes of alpha-and beta-thalassemia carriers in Hong Kong-implications for population screening. N Engl J Med 1997; 336: 1298–1301.
Miyoshi K, Kaneto Y, Kawai H, et al. X-linked dominant control of F-cells in normal adult life: characterization of the Swiss type as hereditary persistence of fetal hemoglobin regulated dominantly by gene(s) on X chromosome. Blood 1988; 72: 1854–1860.
Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739–761.
Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332: 918–922.
Orkin SH. Transcription factors and hematopoietic development. J Biol Chem 1995; 270: 4955–4958.
Pâszty C. Transgenic and gene knock-out mouse models of sickle cell anemia and the thalassemias. Curr Opin Hematol 1997; 4: 88–93.
Pâszty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, Rubin EM. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997; 278: 876–878.
Perkins AC, Gaensler KM, Orkin SH. Silencing of human fetal globin expression is impaired in the absence of the adult beta-globin gene activator protein EKLF. Proc Natl Acad Sci USA 1996;93:12, 267–12, 271.
Rochette J, Craig JE, Thein SL. Fetal hemoglobin levels in adults. Blood Reviews 1994; 8: 213–224.
Rodgers GP, Rachmilewitz EA. Novel treatment options in the severe (3-globin disorders. Br J Haematol 1995; 91: 263–268.
Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science 1997; 278: 873–876.
Serjeant GR. Sickle Cell Disease, 2nd ed. Oxford: Oxford University Press, 1992.
Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus HE. The Molecular Basis of Blood Diseases, 2nd ed. Philadelphia: WB Saunders, 1994.
Stamatoyannopoulos JA, Nienhuis AW. Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Annu Rev Med 1993; 43: 497–521.
Stasiak A, West SC, Egelman EH. Sickle cell anemia research and a recombinant DNA technique. Science 1997; 277: 460–462.
Steinberg MH, Lu Z-H, Barton FB, Terrin ML, Charache S, Dover GJ. Multicenter Study of Hydroxyurea: fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 1997; 89: 1078–1088.
Their) SL. Dominant ß thalassaemia: molecular basis and pathophysiology. Br J Haematol 1992; 80: 273–277.
Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. Oxford: Blackwell Scientific, 1981.
Wilkie AOM, Buckle VJ, Harris PC, et al. Clinical features and molecular analysis of the a thalassemia/mental retardation syndromes. I. Cases due to deletions involving chromosome band 16p13.3. Am J Hum Genet 1990; 46: 1112–1126.
Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci USA 1995;92: 11, 608–11, 612.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Thein, S.L., Rochette, J. (1998). Disorders of Hemoglobin Structure and Synthesis. In: Jameson, J.L. (eds) Principles of Molecular Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-726-0_20
Download citation
DOI: https://doi.org/10.1007/978-1-59259-726-0_20
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-6272-3
Online ISBN: 978-1-59259-726-0
eBook Packages: Springer Book Archive